BioSpace News Archive

Pfizer will acquire the Seattle-based antibody-drug conjugate leader in a $43 billion deal expected to close late in 2023 or early 2024.

A recent report released by accounting and consulting firm BDO showed that over the course of 2023, 13% of life sciences companies may turn to layoffs in response to uncertain economic conditions.

The California Department of Financial Protection and Innovation shut down the Silicon Valley Bank Friday, a top financial institution for the life sciences industry, leaving biopharmas scrambling.

Sanofi will acquire diabetes leader Provention Bio for $25 per share for a total of $2.9 billion, the companies announced Monday.

Given the successes and failures of Merck’s current Keytruda development strategy, a better multi-pronged approach may be needed to optimize current resources.

Innate Pharma does not have any financial exposure to Silicon Valley Bank Innate Pharma SA has learned that Silicon Valley Bank has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver.

ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, announced it does not hold cash deposits nor securities at Silicon Valley Bank.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT Phase III clinical trial with LUMEVOQ®.

Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, continues its progress in the US market.

Calibre Scientific is pleased to announce the acquisition of AlphaScience GmbH, a diagnostics provider with headquarters in Frankfurt, Germany.